Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
August 26, 2026
,
Shah, M. et al.
Clinical Cancer Research
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Zalifrelimab (CTLA-4 Antagonist)
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
Other Articles & Publications
Future Oncology
July 28, 2022
,
O'Malley, et al.
No items found.
Balstilimab (PD-1 inhibitor)
Zalifrelimab (CTLA-4 Antagonist)
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
Other Articles & Publications
Journal of Clinical Oncology
July 28, 2022
,
O'Malley, et al.
No items found.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
ESMO
European Society for Medical Oncology, Gastrointestinal (ESMO- GI)
July 28, 2022
,
Bullock, et al.